"10.1371_journal.pone.0047105","plos one","2012-11-06T00:00:00Z","Christian Eitzinger; Silvia Ehrlenbach; Herbert Lindner; Leopold Kremser; Waldemar Gottardi; Dmitri Debabov; Mark Anderson; Markus Nagl; Dorothea Orth","Department of Hygiene, Microbiology and Social Medicine, Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Innsbruck, Austria; Division of Clinical Biochemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria; NovaBay Pharmaceuticals, Inc., Emeryville, California, United States of America","Conceived and designed the experiments: CE SE HL WG DD MA MN DO. Performed the experiments: CE SE LK. Analyzed the data: CE HL LK DD MN DO. Contributed reagents/materials/analysis tools: HL MN DO. Wrote the paper: CE SE MN DO. Critically revised the data: CE SE HL LK WG DD MA MN DO. Critically revised the manuscript: CE SE HL LK WG DD MA MN DO. Final approval of the manuscript: CE SE HL LK WG DD MA MN DO.","Dmitri Debabov and Mark Anderson are employed by and Markus Nagl was a consultant for NovaBay Pharmaceuticals, Inc., the funder of this study. In this study, pure NVC-612 (molecular weight 209.63 g/mol) and NVC-422 (molecular weight 244.07 g/mol) were from NovaBay Pharmaceuticals Inc. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","11","Christian Eitzinger","CE",9,TRUE,8,3,6,4,TRUE,TRUE,FALSE,0,NA,FALSE
